The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.
Antigen or mitogen-induced activation of resting T cells induces the synthesis of interleukin-2 (IL-2) as well as the expression of specific cell surface receptors for this lymphokine. Failure of the production of either IL-2 or its receptor results in a failure of the T-cell immune response. The receptor is composed of a 33,000-dalton (251-amino acid) peptide precursor that is post-translationally glycosylated into the mature 55,000-dalton form. In contrast to resting T cells, human T-cell lymphotrophic virus I (HTLV-I)-associated adult T-cell leukemia cells constitutively express large numbers of IL-2 receptors. Because IL-2 receptors are present on the malignant T cells but not on normal resting cells, clinical trials have been initiated in which patients with adult T-cell leukemia are treated with a monoclonal antibody that binds to the IL-2 receptor.
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000502:physiology; D002986:Clinical Trials as Topic; D003001:Cloning, Molecular; D004247:DNA / Q000235:genetics; D017977:Deltaretrovirus / Q000502:physiology; D005786:Gene Expression Regulation; D006801:Humans; D007376:Interleukin-2 / Q000502:physiology; D007938:Leukemia / Q000276:immunology* / Q000628:therapy; D008214:Lymphocytes / Q000382:microbiology / Q000502:physiology*; D051379:Mice / Q000276:immunology; D011971:Receptors, Immunologic / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D015375:Receptors, Interleukin-2; D013601:T-Lymphocytes / Q000502:physiology
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D004247:DNA